Oncotarget

Research Papers:

Extranodal extension status is a powerful prognostic factor in stage III colorectal cancer

Chan Wook Kim, Jihun Kim, Seung-Seop Yeom, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Seunghee Baek, Chang Sik Yu and Jin Cheon Kim _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:61393-61403. https://doi.org/10.18632/oncotarget.18223

Metrics: PDF 465 views  |   HTML 1188 views  |   ?  


Abstract

Chan Wook Kim1, Jihun Kim2, Seung-Seop Yeom1, Jong Lyul Lee1, Yong Sik Yoon1, In Ja Park1, Seok-Byung Lim1, Seunghee Baek3, Chang Sik Yu1 and Jin Cheon Kim1

1Department of Surgery, University of Ulsan College of Medicine, Institute of Innovative Cancer Research, Asan Medical Center, Seoul, Korea

2Department of Pathology, University of Ulsan College of Medicine, Institute of Innovative Cancer Research, Asan Medical Center, Seoul, Korea

3Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

Correspondence to:

Jin Cheon Kim, email: jckim@amc.seoul.kr

Keywords: colorectal cancer, lymph node, extranodal extension, stage III, prognosis

Received: March 20, 2017     Accepted: April 12, 2017     Published: May 26, 2017

ABSTRACT

Purpose: The present study aimed to evaluate the clinicopathologic characteristics of patients with extranodal extension (ENE) and the prognostic implications of ENE in stage III colorectal cancer (CRC).

Results: ENE was more frequent in younger patients and those with rectal cancer, higher T stage, higher N stage, lymphovascular invasion (LVI), and perineural invasion (PNI). Five-year disease-free survival (DFS) and overall survival (OS) were lower in patients with ENE-positive than in those with ENE-negative tumors (DFS, 66.4% vs. 80.1%; and OS, 74.8% vs. 85.6%, respectively; P < 0.001 both). In multivariate analysis, pathologic stage, the presence of ENE, LVI, PNI, and no adjuvant chemotherapy were significant independent prognostic factors for DFS and OS. There were no statistically significant differences in DFS and OS between ENE-positive stage IIIB tumors and ENE-negative stage IIIC tumors.

Materials and Methods: The records of 1,948 stage III CRC patients who underwent curative surgery between January 2003 and December 2010 were retrospectively reviewed.

Conclusions: The presence of ENE is independently and significantly associated with lower DFS and OS rates after curative resection for stage III CRC. ENE status should be considered in both the pathologic report and CRC staging system.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18223